REYATAZ
Total Payments
$614,262
Transactions
90
Doctors
58
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $312.13 | 13 | 12 |
| 2019 | $757.33 | 2 | 2 |
| 2018 | $25,987 | 6 | 1 |
| 2017 | $587,205 | 69 | 45 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $612,977 | 19 | 99.8% |
| Food and Beverage | $1,284 | 71 | 0.2% |
Payments by Type
Research
$612,977
19 transactions
General
$1,284
71 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Cardiovascular renal and bone outcomes of combination antiretroviral therapy A national cohort study of Veterans | E.R. Squibb & Sons, L.L.C. | $351,445 | 0 |
| CNICS Collaboration Investigating CV outcomes amongst ARVs | E.R. Squibb & Sons, L.L.C. | $135,917 | 0 |
| To understand relevance of candidate therapeutic targets and pathways in cardiac tissues from normal healthy control heart failure subjects | E.R. Squibb & Sons, L.L.C. | $44,321 | 0 |
| Durability and Prescribing Patterns of Contemporary Antiretroviral Agents in Treatment Naive Persons Living with HIV | E.R. Squibb & Sons, L.L.C. | $25,000 | 0 |
| Predicting Subclinical Cardiovascular Disease in HIV infected Women using a Biomarker Score | E.R. Squibb & Sons, L.L.C. | $25,000 | 0 |
| 2016 R 0033 Evaluation of Atazanavir in delayed progression of HIV CIMT via the Kynurenine Pathway | E.R. Squibb & Sons, L.L.C. | $20,000 | 0 |
| Atazanavir and Endothelial Function in Older HIV Patients | E.R. Squibb & Sons, L.L.C. | $9,384 | 0 |
| Antiretroviral Pregnancy Registry | E.R. Squibb & Sons, L.L.C. | $1,085 | 2 |
| Trial Consulting Services birth defect evaluations | E.R. Squibb & Sons, L.L.C. | $740.92 | 1 |
| A Randomized Double Blind Double Dummy Positive Controlled Crossover Study to Determine Electrocardiographic Effects of BMS 955176 in Healthy Subjects | E.R. Squibb & Sons, L.L.C. | $84.00 | 1 |
Top Doctors Receiving Payments for REYATAZ — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Infectious Disease | West Palm Beach, FL | $21.05 | 1 |
| , M.D | Infectious Disease | West Palm Beach, FL | $21.05 | 1 |
| , M.D | Infectious Disease | West Palm Beach, FL | $21.05 | 1 |
| , MD | Infectious Disease | Aventura, FL | $18.06 | 1 |
| , M.D | Internal Medicine | Miami, FL | $17.67 | 1 |
| , MD | Infectious Disease | Aventura, FL | $17.64 | 1 |
| Raymond Elliott | — | Fort Lauderdale, FL | $17.00 | 1 |
| , DO | Family Medicine | Fort Lauderdale, FL | $17.00 | 1 |
| , D.O | Internal Medicine | Oakland Park, FL | $16.74 | 1 |
| , M.D | Internal Medicine | Oakland Park, FL | $16.74 | 1 |
| , D.O | Family Medicine | Oakland Park, FL | $16.74 | 1 |
| , M.D | Family Medicine | Oakland Park, FL | $16.74 | 1 |
| , D.O | Internal Medicine | Oakland Park, FL | $16.74 | 1 |
| , M.D | Infectious Disease | Miami Beach, FL | $16.62 | 1 |
| , M.D | Infectious Disease | Miami Beach, FL | $16.62 | 1 |
| , M.D | Internal Medicine | Miami Beach, FL | $16.62 | 1 |
| , M.D | Hematology & Oncology | Ocala, FL | $16.41 | 1 |
| Michael Hin | — | Miami, FL | $16.03 | 2 |
| , M.D | Infectious Disease | Aventura, FL | $15.48 | 1 |
| , MD | Infectious Disease | West Palm Beach, FL | $15.24 | 1 |
| , MD | Infectious Disease | West Palm Beach, FL | $15.24 | 1 |
| , M.D | Infectious Disease | Miami, FL | $14.21 | 1 |
| , D.O | Family Medicine | Wilton Manors, FL | $14.21 | 1 |
| , M.D | Family Medicine | Harlingen, TX | $13.00 | 1 |
| , M.D | Obstetrics & Gynecology | Harlingen, TX | $13.00 | 1 |
Ad
Manufacturing Companies
- E.R. Squibb & Sons, L.L.C. $614,164
- Celgene Corporation $97.84
Product Information
- Type Drug
- Total Payments $614,262
- Total Doctors 58
- Transactions 90
About REYATAZ
REYATAZ is a drug associated with $614,262 in payments to 58 healthcare providers, recorded across 90 transactions in the CMS Open Payments database. The primary manufacturer is E.R. Squibb & Sons, L.L.C..
Payment data is available from 2017 to 2024. In 2024, $312.13 was paid across 13 transactions to 12 doctors.
The most common payment nature for REYATAZ is "Unspecified" ($612,977, 99.8% of total).
REYATAZ is associated with 10 research studies, including "Cardiovascular renal and bone outcomes of combination antiretroviral therapy A national cohort study of Veterans" ($351,445).